Koronis Pharmaceuticals

Koronis Pharmaceuticals was founded in 1998 in the Seattle area as a biotechnology company focused on antiviral drug discovery and development. Its central scientific proposition was Viral Decay Acceleration, commonly abbreviated VDA. The platform was intended to exploit the high mutation rate of viruses: by encouraging the accumulation of harmful mutations during viral replication, a VDA-based medicine might reduce the viability of a viral population. This represented an alternative research direction to antiviral medicines designed mainly around direct inhibition of viral proteins or replication enzymes. Koronis identified HIV infection as its principal therapeutic focus. Its lead candidate, KP-1461, was developed as an investigational antiviral for people with HIV. Public descriptions of the company characterize KP-1461 as the primary product candidate and the leading practical application of the VDA platform. The available material does not establish a commercial launch or approval, and no verified evidence in the supplied sources indicates that KP-1461 became a marketed medicine. The company also pursued antiviral programs for hepatitis C and respiratory syncytial virus. These activities broadened the potential application of the underlying technology beyond HIV, covering both a chronic viral infection and a respiratory viral disease. The reference material does not name the individual HCV or RSV candidates, and it does not provide sufficient information to reconstruct their clinical stages, trial results, regulatory submissions, or commercial outcomes. During its development as a biotechnology venture, Koronis was associated with consideration of an initial public offering. A Reuters article is identified among the company’s external references as reporting on IPO prospects, but the available material does not confirm that the company completed an IPO or became publicly traded. No ticker, listing exchange, verified corporate website, or financial data is supplied. The available reference record is brief and does not document the company’s later ownership, mergers, acquisitions, executive leadership, financing history, clinical milestones, or present-day operations. As a result, Koronis Pharmaceuticals is best described on the available evidence as a historically documented antiviral biotechnology company whose current status cannot be determined from the supplied sources.

• 1998

  Company founded

  [1]Koronis Pharmaceuticalsen.wikipedia.org

  Koronis Pharmaceuticals was established as a Seattle-area biotechnology company focused on antiviral therapeutics.

Antiviral drug-development biotechnology company using Viral Decay Acceleration technology.

• HIV antiviral drug candidate

  KP-1461

  KP-1461 was Koronis Pharmaceuticals’ lead disclosed product candidate and was developed for the treatment of human immunodeficiency virus infection. It was presented as an application of the company’s Viral Decay Acceleration approach, which sought to weaken viral populations by accelerating the accumulation of harmful mutations. The supplied material does not establish that KP-1461 received regulatory approval or reached commercial sale.

• HCV antiviral drug development

  Hepatitis C antiviral program

  Koronis reported additional products or research programs intended for hepatitis C treatment. The available reference does not identify a specific candidate name, clinical stage, mechanism beyond the company’s broader VDA platform, regulatory status, or commercial outcome.

• RSV antiviral drug development

  RSV antiviral program

  The company also reported antiviral development work for respiratory syncytial virus infection. No specific product name, clinical milestone, approval, or launch information is available in the supplied sources.

1. 1Koronis Pharmaceuticalsen.wikipedia.org